Navigate Fool.com
Will ALKS beat
the market?

Alkermes, Inc. (NASDAQ: ALKS)

Community Rating: 3 Stars: Appealing

46.21 0.79 (1.74%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $45.62
Previous Close $45.42
Daily Range $45.41 - $46.44
52-Week Range $28.86 - $54.25
Market Cap $6.7B
P/E Ratio -4,542.00
Dividend (Yield) $0.00 (0.0%)
Volume 527,399
Average Daily Volume 735,335
Current FY EPS $0.17

How do you think ALKS
will perform against the market?

Top ALKS Bull/Bear Pitches


TerryFool (12.11)
Submitted March 17, 2014

BUY@ 50 FOR 2015 EPS 2YR 50% 5YR 18%

0 Replies Reply Report this Post

PickThatBooger (< 20)
Submitted November 15, 2010

Almost got the top on this one.

0 Replies Reply Report this Post

News & Commentary Rss Feed

Is Alkermes plc Stock Undervalued?

Strong science and underserved markets can fuel further gains from this delivery-focused biopharma

Why Mylan Should Buy Alkermes

The recent wave of tax inversion deals creates investment opportunities for healthcare companies headquartered in countries with low corporate tax rates. Alkermes is an attractive target and a likely suitor for this company is Mylan, which has already expressed an interest in undergoing tax inversion.

3 Stocks Scoring for Investors

Three health care stocks to consider for your watchlist.

Sector Update: Healthcare

Sector Update: Healthcare Shares Flat Pre-Market; Pfizer Teams with Cellectis on Immunotherapy

Credit Suisse Adds New Stocks in Multiple Sectors to Top Picks List

Top Analyst Upgrades and Downgrades: J.C. Penney, Micron, Twitter, NBG, SanDisk and More

Sector Update: Healthcare

Sector Update: Healthcare Shares Mixed Pre-Market; WellPoint up 2% on Q1 Results

The Biggest Biotech Wins of the Week

Find out which biotech and pharmaceutical companies posted the best clinical results for the week ending April 11.

See More ALKS News...





Alkermes, Inc. (ALKS) Description

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Website: http://www.alkermes.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks